A new option

New fixed-dosed two-drug regimen approved for HIV—reducing patient exposure and potential drug interactions compared to usual pills containing three or more medicines The TGA has approved Dovato (dolutegravir and lamivudine), a new once-daily, single-tablet, two-drug regimen for treatment-naïve adults and adolescents with human immunodeficiency virus infection type 1 (HIV-1). Studies show that that Dovato, containing